α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females

Published on Feb 1, 2020in Clinica Chimica Acta2.615
· DOI :10.1016/J.CCA.2019.10.031
Galina Baydakova4
Estimated H-index: 4
Alexandra Ilyushkina + 4 AuthorsEkaterina Zakharova5
Estimated H-index: 5
Abstract Fabry disease (FD [MIM:301500]) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene. Deficient activity of its product, lysosomal enzyme α-galactosidase A (α-Gal A), leads to excessive accumulation of glycosphingolipids in cells of multiple organs. The establishing of the diagnosis is challenge in female patients because of milder clinical manifestation and normal α-Gal A activity. The globotriaosylsphingosine (lysoGb3) is described as a more sensitive diagnostic biomarker for females with pathogenic mutation in the GLA gene. Thus, the aim of this study is to improve the biochemical diagnostic efficiency for FD in females. Here we report the α-Gal A/lysoGb3 ratio as the novel biochemical criteria for diagnosis of female patients with FD, using dried blood spots (DBS) as test samples. It showed 100% sensitivity in distinguishing our group of 35 female patients from control (n=140). Whereas meassuremnt of α-Gal A and lysoGb3 alone showed 8.6% and 74.4% respectively. A new approach of using the ratio of α-Gal A activity to lysoGb3 concentration in DBS may provides a more accurate screening tool for identification of FD females.
📖 Papers frequently viewed together
5 Citations
1 Citations
1 Citations
#1Tsong-Hai Lee (CGU: Chang Gung University)H-Index: 24
#2Jen-Tsung Yang (CGU: Chang Gung University)H-Index: 18
Last. A. P. BurlinaH-Index: 1
view all 10 authors...
BACKGROUND AND PURPOSE: Fabry disease is an X-linked disease, and enzyme-based screening methods are not suitable for female patients. METHODS: In total, 1000 young stroke patients (18-55 years, 661 with ischaemic stroke and 339 with hypertensive intracerebral hemorrhage) were recruited. The Sequenom iPLEX assay was used to detect 26 Fabry related mutation genes. The frequency of Fabry disease in young stroke was reviewed and compared between Asian and non-Asian countries. RESULTS: Two male pati...
8 CitationsSource
#1Hiroki Maruyama (Niigata University)H-Index: 26
#2Kaori Miyata (Genzyme)H-Index: 2
Last. Satoshi IshiiH-Index: 9
view all 31 authors...
The HTML version of this Article contained errors in Supplementary Figure S2 “Flowchart of the lyso-Gb3 screening and gene analysis in female patients”, which have been detailed in the associated Correction.
33 CitationsSource
#1Darrell B. Newman (Mayo Clinic)H-Index: 5
#2William R. Miranda (Mayo Clinic)H-Index: 14
Last. Michael J. Ackerman (Mayo Clinic)H-Index: 144
view all 8 authors...
Abstract The prevalence of Fabry disease (FD) in adult patients with suspected hypertrophic cardiomyopathy (HCM) has been reported between 0.3% and 4%. Fabry disease–specific therapy necessitates early diagnosis; however, the optimal screening strategy and cost efficacy of routine α-galactosidase A (α-gal A) vs comprehensive galactosidase alpha gene (GLA) testing remain poorly understood. We identified 1192 patients who underwent routine α-gal A screening between January 1, 2011, and December 31...
3 CitationsSource
#1Giovanni Duro (National Research Council)H-Index: 20
#2Carmela Zizzo (National Research Council)H-Index: 12
Last. Paolo ColombaH-Index: 12
view all 41 authors...
Anderson-Fabry disease (FD) is a rare, progressive, multisystem storage disorder caused by the partial or total deficit of the lysosomal enzyme α-galactosidase A (α-Gal A). It is an X-linked, lysosomal enzymopathy due to mutations in the galactosidase alpha gene (GLA), encoding the α-Gal A. To date, more than 900 mutations in this gene have been described. In our laboratories, the study of genetic and enzymatic alterations related to FD was performed in about 17,000 subjects with a symptomatolog...
31 CitationsSource
#1S N Pchelina (Petersburg Nuclear Physics Institute)H-Index: 8
#2Galina BaydakovaH-Index: 4
view all 13 authors...
INTRODUCTION: Glucocerebrosidase 1 mutations, the most common genetic contributor to Parkinson's disease (PD), have been associated with decreased glucocerebrosidase enzymatic activity in PD patients with glucocerebrosidase 1 mutations (glucocerebrosidase 1-PD). However, it is unknown whether this decrease in enzymatic activity leads to lysosphingolipid accumulations. METHODS: The levels of hexosylsphingosines, globotriaosylsphingosine, sphingomyelin, and sphingomyelin-509 were measured in dried...
19 CitationsSource
#1L. Lavalle (Royal Free Hospital)H-Index: 1
#2A. S. Thomas (Barts Health NHS Trust)H-Index: 1
Last. Derralynn Hughes (Royal Free Hospital)H-Index: 58
view all 9 authors...
Background Fabry disease (FD) results from X-linked inheritance of a mutation in the GLA gene, encoding for alpha galactosidase A, and is characterized by heterogeneous clinical manifestations. Two phenotypes have been described “Classic” and “late onset” which cannot be predicted exclusively by genotype. The latter has been considered an attenuated form of the disease often affecting a single organ system commonly the heart. Recent studies have demonstrated that cardiac outcomes are similar in ...
21 CitationsSource
Background Lysosomal storage diseases (LSDs) are inborn errors of metabolism resulting from 50 different inherited disorders. The increasing availability of treatments and the importance of early intervention have stimulated newborn screening (NBS) to diagnose LSDs and permit early intervention to prevent irreversible impairment or severe disability. We present our experience screening newborns in North East Italy to identify neonates with Mucopolysaccharidosis type I (MPS I) and Pompe, Fabry, a...
62 CitationsSource
#1M. Voorink-Moret (UvA: University of Amsterdam)H-Index: 1
#2Susanna M. I. Goorden (UvA: University of Amsterdam)H-Index: 3
Last. Frédéric M. Vaz (UvA: University of Amsterdam)H-Index: 47
view all 10 authors...
Abstract Background In patients suspected of a lipid storage disorder (sphingolipidoses, lipidoses), confirmation of the diagnosis relies predominantly on the measurement of specific enzymatic activities and genetic studies. New UPLC-MS/MS methods have been developed to measure lysosphingolipids and oxysterols, which, combined with chitotriosidase activity may represent a rapid first tier screening for lipid storage disorders. Material and methods A lysosphingolipid panel consisting of lysoglobo...
21 CitationsSource
#1Albina Nowak (UZH: University of Zurich)H-Index: 15
#2Thomas P. MechtlerH-Index: 14
Last. Robert J. Desnick (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 120
view all 4 authors...
Abstract Background Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of α-galactosidase A (α-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). Here, we compared the levels of Lyso-Gb3 in dried blood spots (DBS) and sera in affected males and heterozygotes with the “Classic” and “Later-Onset” phenotypes. Methods The Lyso-Gb3 concentrations in DBS and sera fr...
30 CitationsSource
#1Albina Nowak (UZH: University of Zurich)H-Index: 15
#2Thomas P. MechtlerH-Index: 14
Last. David C. KasperH-Index: 22
view all 7 authors...
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the α-galac-tosidase A (GLA) gene causing deficiency of α-galactosidase A which results in progressive glycosphingolipid ac-cumulation, especially globotriaosylceramide (Gb3), in body liquids and lysosomes. In a large cohort of FD patients, we aimed to establish genotype/phenotype relations as indicated by serum LysoGb3 (deacylated Gb3). Methods: In 69 consecutive adult FD patients (males: n =28(41%...
40 CitationsSource
Cited By6
#1Hiroki Maruyama (Niigata University)H-Index: 26
#2Atsumi Taguchi (Niigata University)H-Index: 5
Last. Norio Sakai (Osaka University)H-Index: 37
view all 19 authors...
Fabry disease is an X-linked disorder of α-galactosidase A (GLA) deficiency. Our previous interim analysis (1 July 2014 to 31 December 2015) revealed plasma globotriaosylsphingosine as a promising primary screening biomarker for Fabry disease probands. Herein, we report the final results, including patients enrolled from 1 January to 31 December 2016 for evaluating the potential of plasma globotriaosylsphingosine and GLA activity as a combined screening marker. We screened 5691 patients (3439 ma...
Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pathogenic mechanisms in which several mediators could be implicated, inducing multiorgan lesions, mainly in the kidney, heart and nervous system, resulting in clinical manifestations of the disease. Enz...
#1Martin MichaudH-Index: 6
#2Wladimir MauhinH-Index: 5
Last. Francis GachesH-Index: 3
view all 8 authors...
Fabry disease is the second most frequent lysosomal storage disorder. It is a X-linked genetic disease secondary to alpha-galactosidase A enzyme deficiency. This is a progressive and systemic disease that affects both males and females. Classical symptoms and organ involvements are acral pain crisis, cornea verticillata, hypertrophic cardiomyopathy, stroke and chronic kidney disease with proteinuria. Nevertheless, organ damages can be missing or pauci-symptomatic and other common symptoms are po...
1 CitationsSource
#1Albina NowakH-Index: 15
#2Felix Beuschlein (UZH: University of Zurich)H-Index: 80
Last. David G. Warnock (UAB: University of Alabama at Birmingham)H-Index: 87
view all 5 authors...
Background Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the α-galactosidase A gene (GLA) leading to deficiency of α-galactosidase A and ultimately in progressive glycosphingolipid accumulation, especially globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (Lyso-Gb3). The aim of the study was to assess plasma Lyso-Gb3 levels as a possible factor associated with adverse outcomes in FD. Methods In a cohort of 66 patients with...
2 CitationsSource
#1Grigoris Effraimidis (Copenhagen University Hospital)H-Index: 2
#2Ulla Feldt-Rasmussen (Copenhagen University Hospital)H-Index: 70
Last. Christiane Auray-Blais (Université de Sherbrooke)H-Index: 30
view all 7 authors...
Introduction Recent studies showed the usefulness of globotriaosylsphingosine (lyso-Gb3) and related analogues, deacylated forms of globotriaosylceramide (Gb3), for high-risk screening, treatment monitoring and follow-up for patients with Fabry disease. Methods We evaluated Gb3, lyso-Gb3 and analogues using tandem mass spectrometry in 57 women with Fabry disease followed during a period of 15.4 years. Twenty-one women were never treated and 36 received treatment (agalsidase-beta, n=30; agalsidas...
3 CitationsSource
Abstract Fabry disease is a frequent lysosomal storage disorder secondary to the deficiency of alpha-galactosidase A enzyme. This X-linked genetic disease realizes progressive and systemic manifestations that affect both male and female. Fabry disease may present as “classical”, as “late-onset” or “non-classical” forms. Symptoms and organ involvements of classical Fabry disease are acral pain crisis, cornea verticillata, hypertrophic cardiomyopathy, stroke and chronic kidney disease with protein...
3 CitationsSource